{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:44:14Z","timestamp":1790376254924,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.xkme.2019.12.006","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T20:43:28Z","timestamp":1582317808000},"page":"218-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["SGLT2 Inhibitor\u2013Induced Euglycemic Diabetic Ketoacidosis: A Case Report"],"prefix":"10.1016","volume":"2","author":[{"given":"Katherine M.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Isom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xkme.2019.12.006_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2019.03.014","article-title":"Euglycemic diabetic ketoacidosis","volume":"63","author":"Barski","year":"2019","journal-title":"Eur J Intern Med"},{"issue":"5866","key":"10.1016\/j.xkme.2019.12.006_bib2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/bmj.2.5866.578","article-title":"Euglycemic diabetic ketoacidosis","volume":"2","author":"Munro","year":"1973","journal-title":"Br Med J"},{"issue":"23","key":"10.1016\/j.xkme.2019.12.006_bib5","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1056\/NEJMc1701990","article-title":"Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor","volume":"376","author":"Fralick","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.xkme.2019.12.006_bib6","doi-asserted-by":"crossref","first-page":"E47","DOI":"10.2337\/dc17-1721","article-title":"SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications","volume":"41","author":"Meyer","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.xkme.2019.12.006_bib7","doi-asserted-by":"crossref","DOI":"10.15277\/bjd.2016.112","article-title":"Association of British Clinical Diabetologists (ABCD) position statement on the risk of diabetic ketoacidosis associated with the use of sodium-glucose cotransporter-2 inhibitors","volume":"16","author":"Dashora","year":"2016","journal-title":"Br J Diabetes"},{"issue":"3","key":"10.1016\/j.xkme.2019.12.006_bib8","article-title":"Management of hyperglycemic crises diabetic ketoacidosis and hyperglycemic hyperosmolar state","volume":"101","author":"Fayfman","year":"2017","journal-title":"Med Clin North Am"},{"issue":"24","key":"10.1016\/j.xkme.2019.12.006_bib9","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1056\/NEJM197406132902405","article-title":"Current concepts - diabetic ketoacidosis","volume":"290","author":"Felig","year":"1974","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.xkme.2019.12.006_bib10","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/anae.14251","article-title":"Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations","volume":"73","author":"Milder","year":"2018","journal-title":"Anaesthesia"},{"key":"10.1016\/j.xkme.2019.12.006_bib11","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41467-019-08466-w","article-title":"Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats","volume":"10","author":"Perry","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.xkme.2019.12.006_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2019.01.002","article-title":"SGLT2 inhibitors and metformin: dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes","volume":"846","author":"Donnan","year":"2019","journal-title":"Eur J Pharmacol"},{"issue":"suppl 1","key":"10.1016\/j.xkme.2019.12.006_bib13","first-page":"S90","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019","volume":"42","author":"Cefalu","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.xkme.2019.12.006_bib14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/nep.13039","article-title":"Dapagliflozin associated ketoacidosis: a must know fact for nephrologists","volume":"23","author":"Chan","year":"2018","journal-title":"Nephrology"},{"key":"10.1016\/j.xkme.2019.12.006_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/IJNRD.S135899","article-title":"Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions","volume":"10","author":"D'Elia","year":"2017","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"6","key":"10.1016\/j.xkme.2019.12.006_bib16","first-page":"XI","article-title":"Metabolic acidosis in a patient with type 2 diabetes","volume":"69","author":"Kohli","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.xkme.2019.12.006_bib17","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.xkme.2019.12.006_bib18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.xkme.2019.12.006_bib19","article-title":"Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin","volume":"5","author":"Pujara","year":"2017","journal-title":"J\u00a0Invest Med High Impact Case Rep"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059520300315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059520300315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:19:48Z","timestamp":1762910388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059520300315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S2590059520300315"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2019.12.006","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 Inhibitor\u2013Induced Euglycemic Diabetic Ketoacidosis: A Case Report","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2019.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}